Optimizing Clinical Advances in Mild Cognitive Impairment and Early Alzheimer's
| Target Professions: | DO, MD, Nurse, Nurse Practitioner, Physician Assistant, MBBS |
| Target Specialties: | Neurology, Geriatric Psychiatry, Geriatrics, Radiology |
| Credits Available: | 4.50 AMA PRA Category 1 Credit™ & 4.50 MOC points |
It is well recognized that early diagnosis and ongoing management of Alzheimer’s Disease (AD) requires a patient-centric, highly coordinated effort among a large multidisciplinary team of clinicians. As such, this proposed initiative establishes meaningful, small group interactions among key stakeholders (neurologists, dementia specialists, geriatricians, geriatric psychologists, radiologists, and primary care clinicians) that will, through a variety of collaborative educational experiences, help all members of the care team consider approaches to reducing barriers to effective coordinated care and encourages each participant to create an action plan to improve the quality of AD care delivered within their organization. Considering the complexity of this challenge, lack of expertise, and the breadth of communication and cooperation required, participants would highly benefit from an educational intervention that includes discussions with knowledgeable experts and peers from within and outside of their own communities who can share experiences, strategies, challenges, and success stories.
CME/CE Accreditation Information
Itinerary
Part 1
The following questions are designed to assess your knowledge and practice of patients with early-stage Alzheimer's disease.
This module focuses on the diagnosis and early recognition of Alzheimer’s disease (AD) and mild cognitive impairment (MCI) and the current and future use of biomarkers in AD diagnosis and management.
This module will cover monoclonal antibodies, both emerging and approved, for use in treating early AD (mild cognitive impairment due to AD or mild dementia due to AD): donanemab and lecanemab.
This module will cover patient selection for monoclonal antibodies in early AD with a particular eye towards minimizing the risk of amyloid-related imaging abnormalities (ARIAs). This module will also focus on lecanemab, as it is currently the only approved agent for early AD.
This module will cover the growing role of primary care providers and other healthcare providers in the multidisciplinary management of patients with AD.
The following questions are designed to assess your gained knowledge and practice of patients with early-stage Alzheimer's disease.
During this session, we will review the self-study modules and discuss approaches to treatment that offer optimal care to patients with early-stage Alzheimer's disease.
Part 2
70 year-old female with new diagnosis of MCI secondary to Alzheimer’s disease. Requires further workup. Patient and daughter considering disease-modifying treatment.
In light of the information reviewed and discussed during this program, please share an action plan that you will implement to improve the diagnosis and management for your patients with Alzheimer's Disease.
During this session, we will review the patient case and discuss treatment plans. Additionally, we will share our action plans and how this CME activity will shape our practice regarding patient care.
